CoChat

Attenuation of Experimental Atherosclerosis by Interleukin-19

Open access
Ellison, Stephen, Gabunia, Khatuna, Kelemen, Sheri E., England, Ross N., Scalia, Rosario, Richards, James M., Orr, A. Wayne, Traylor, James G., Rogers, Thomas, Cornwell, William, Berglund, Lisa M., Goncalves, Isabel, Gomez, Maria F., Autieri, Michael V. · 2013 · Arteriosclerosis, Thrombosis, and Vascular Biology
Cited by 58

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Objective—: Interleukin-19 (IL-19) is a putative Th2, anti-inflammatory interleukin. Its expression and potential role in atherogenesis are unknown. IL-19 is not detected in normal artery and is expressed to a greater degree in plaque from symptomatic versus asymptomatic patients, suggesting a compensatory counter-regulatory function. We tested whether IL-19 could reduce atherosclerosis in susceptible mice and identified plausible mechanisms. Approach and Results—: LDLR −/− mice fed an atherogenic diet and injected with either 1.0 or 10.0 ng/g per day recombinant mouse IL-19 had significantly less plaque area in the aortic arch compared with controls ( P <0.0001). Weight gain, cholesterol, and triglyceride levels were not significantly different. Gene expression in splenocytes from IL-19–treated mice demonstrated immune cell Th2 polarization, with decreased expression of T-bet, interferon-γ, interleukin-1β, and interleukin-12β and increased expression of GATA3 and FoxP3 mRNA. A greater percentage of lymphocytes were Th2 polarized in IL-19–treated mice. Cellular characterization of plaque by immunohistochemistry demonstrated that IL-19–treated mice have significantly less macrophage infiltrate compared with controls ( P <0.001). Intravital microscopy revealed significantly less leukocyte adhesion in wild-type mice injected with IL-19 and fed an atherogenic diet compared with controls. Treatment of cultured endothelial cells, vascular smooth muscle cells, and bone marrow–derived macrophages with IL-19 resulted in a significant decrease in chemokine mRNA and mRNA stability protein human antigen R. Conclusions—: These data suggest that IL-19 is a potent inhibitor of experimental atherosclerosis, with diverse mechanisms including immune cell polarization, decrease in macrophage adhesion, and decrease in gene expression. This may identify IL-19 as a novel therapeutic to limit vascular inflammation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/atvbaha.113.301521

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 42

  1. 10.1056/NEJM199901143400207 · DOI · Paper page
  2. 10.1038/nature01323 · DOI · Paper page
  3. 10.1097/01.mol.0000182532.11512.90 · DOI
  4. 10.2353/ajpath.2008.070776 · DOI · Paper page
  5. 10.1038/nri1882 · DOI · Paper page
  6. 10.1124/pr.55.1.5 · DOI · Paper page
  7. 10.1093/cvr/cvn120 · DOI · Paper page
  8. 10.1161/01.res.0000018941.10726.fa · DOI · Paper page
  9. 10.1007/BF03402102 · DOI · Paper page
  10. 10.1096/fj.01-0483fje · DOI · Paper page
  11. 10.1161/01.atv.0000134378.86443.cd · DOI · Paper page
  12. 10.2353/ajpath.2007.060857 · DOI
  13. 10.1016/S0002-9440(10)63471-2 · DOI · Paper page
  14. 10.1038/sj.gene.6363714 · DOI · Paper page
  15. 10.1002/eji.200425523 · DOI · Paper page
  16. 10.1016/j.intimp.2004.01.005 · DOI
  17. 10.1016/j.cytogfr.2010.08.005 · DOI
  18. 10.1517/14728222.11.5.601 · DOI · Paper page
  19. 10.2353/ajpath.2008.080163 · doi:10.2353/ajpath.2008.080163
  20. 10.1016/j.yjmcc.2010.04.016 · DOI
  21. 10.1146/annurev.immunol.22.012703.104622 · DOI · Paper page
  22. 10.1111/j.1365-2133.2005.06665.x · DOI
  23. 10.7150/ijms.7.284 · DOI
  24. 10.1161/atvbaha.110.214916 · DOI
  25. 10.1073/pnas.0409015102 · DOI · Paper page
  26. 10.1161/01.ATV.20.5.1177 · DOI · Paper page
  27. 10.1073/pnas.97.13.6930 · DOI · Paper page
  28. 10.2353/ajpath.2008.070776 · DOI · Paper page
  29. 10.1016/S0021-9150(99)00011-8 · DOI · Paper page
  30. 10.1152/ajpcell.00069.2013 · DOI
  31. 10.1161/01.atv.0000232502.88144.6f · DOI
  32. 10.1016/j.athoracsur.2011.04.061 · doi:10.1016/j.athoracsur.2011.04.061
  33. 10.1016/j.immuni.2005.09.015 · DOI · Paper page
  34. 10.1084/jem.20071868 · DOI · Paper page
  35. 10.1016/S0002-9440(10)63471-2 · DOI · Paper page
  36. 10.1161/circulationaha.109.924886 · DOI · Paper page
  37. 10.1084/jem.20090545 · DOI · Paper page
  38. 10.1038/nm1343 · DOI · Paper page
  39. 10.1371/journal.pone.0000779 · DOI · Paper page
  40. 10.1161/atvbaha.107.149179 · DOI · Paper page
  41. 10.4049/jimmunol.151.2.588 · doi:10.4049/jimmunol.151.2.588
  42. 10.1189/jlb.72.3.503 · DOI

Cited by

See all 58

Metadata

Authors
Ellison, S., Gabunia, K., Kelemen, S. E., England, R. N., Scalia, R., Richards, J. M., Orr, A. W., Traylor, J. G., Rogers, T., Cornwell, W., Berglund, L. M., Goncalves, I., Gomez, M. F., & Autieri, M. V.
Venue
Arteriosclerosis, Thrombosis, and Vascular Biology
Published
2013-10
Volume
33
Issue
10
Pages
2316-2324
ISSN
  • 1079-5642 (ISSN-L)
  • 1524-4636
OpenAlex
W2116973505
Cited by
58
References
1
FWCI
2.67
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Attenuation of Experimental Atherosclerosis by Interleukin-19. https://app.cochat.ai/papers/10.1161/atvbaha.113.301521
The paper
Ellison, S., Gabunia, K., Kelemen, S. E., England, R. N., Scalia, R., Richards, J. M., Orr, A. W., Traylor, J. G., Rogers, T., Cornwell, W., Berglund, L. M., Goncalves, I., Gomez, M. F., & Autieri, M. V. (2013). Attenuation of Experimental Atherosclerosis by Interleukin-19. Arteriosclerosis, Thrombosis, and Vascular Biology. https://doi.org/10.1161/atvbaha.113.301521

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.